Logo

American Heart Association

  24
  0


Final ID: MP2341

Risk Scores Only Weakly Predict Volume of Non-Calcified Coronary Plaque among People with HIV

Abstract Body (Do not enter title and authors here): Background/introduction: Atherosclerotic cardiovascular disease (ASCVD) risk calculators perform poorly among people with HIV (PWH). Non-calcified coronary plaque (NCP) volume measured using coronary computed tomographic angiography (CCTA) predicts future ASCVD events in the general population, and NCP is increased among PWH. However, the ability of ASCVD risk calculators to predict NCP among PWH is unknown.
Methods: We included individuals ages 40-79 with treated and suppressed HIV and ≥ 1 additional cardiovascular risk factor besides HIV. We measured blood pressure and fasting lipid panels. CCTA was performed according to standard research protocol and interpreted by a blinded core lab. The primary outcome was non-calcified plaque volume (excluding calcified plaque). We calculated predicted 10-year atherosclerotic ASCVD risk using four equations: Predicting Risk of cardiovascular disease EVENTs (PREVENT), Pooled Cohort Equation (PCE), Data Collection on Adverse Events of Antiretroviral Drugs (DAD-reduced)-an HIV specific calculator, and Framingham. We used linear regression to assess the amount of variation in log-transformed NCP volume explained by each risk prediction equation.
Results: We included 81 individuals with mean age of 60 years, 4% female (Table). The mean total cholesterol, calculated LDL-C, HDL-C, and triglycerides were 190 mg/dl, 113 mg/dl, 49 mg/dl, and 143 mg/dl, respectively. The mean predicted 10-year ASCVD risk was 5.4% using PREVENT, 12.3% using PCE, 11.5% using DAD, and 17.0% using Framingham.
Predicted risk with each of the four equations correlated with NCP volume (p<0.01 for each), and predicted risk was higher among those with more plaque with all four (Table). However, the proportion of variance in NCP volume explained by each model was low with R2 values of 16.4%, 11.1%, 11.7%, and 11.1% for PREVENT, PCE, DAD, and Framingham, respectively (Figure, p<0.01 for each). Among those with <5% calculated 10-year risk (“low risk”), median plaque volume was 69 mm3 for PREVENT (45 people), 23 mm3 for PCE (15 people), 14 mm3 for DAD (11 people), and 8 mm3 for Framingham (2 people).
Conclusions: Both traditional and HIV specific ASCVD risk prediction equations only explain a small amount of the variation in NCP volume among PWH at elevated cardiovascular risk; this finding may underlie the poor performance of these risk calculators to predict cardiovascular events among this high-risk population.
  • Durstenfeld, Matthew  ( UCSF , San Francisco , California , United States )
  • Levkova, Marta  ( UCSF , San Francisco , California , United States )
  • Jung, Matthias  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Karady, Julia  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Li, Danny  ( UC San Francisco , San Francisco , California , United States )
  • Schaffer, Veronica  ( University of California Los Angeles , Los Angeles , California , United States )
  • Lu, Michael  ( Massachusetts General Hospital , Wellesley , Massachusetts , United States )
  • Hsue, Priscilla  ( University of California Los Angeles , Los Angeles , California , United States )
  • Author Disclosures:
    Matthew Durstenfeld: DO have relevant financial relationships ; Consultant:Merck:Past (completed) | Marta Levkova-Clark: DO NOT have relevant financial relationships | Matthias Jung: No Answer | Julia Karady: No Answer | Danny Li: No Answer | Veronica Schaffer: DO NOT have relevant financial relationships | Michael Lu: DO have relevant financial relationships ; Research Funding (PI or named investigator):Ionis:Active (exists now) ; Research Funding (PI or named investigator):Risk Management Foundation of the Harvard Medical Institutions Incorporated:Active (exists now) | Priscilla Hsue: DO have relevant financial relationships ; Consultant:Gilead:Past (completed) ; Advisor:Marea Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Abbott:Past (completed) ; Consultant:Genentech:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

AI-Powered Multimodal Imaging and ECG for Disease-Specific Diagnostics

Monday, 11/10/2025 , 12:15PM - 01:25PM

Moderated Digital Poster Session

More abstracts on this topic:
Anthracycline Cardiotoxicity in Cancer Patients with HIV

Villarrubia Varela Lourdes, Alpert Peter, Rodriguez Carlos, Lili Zhang, Siochi Christian, Bravo Solarte Daniela, Slipczuk Leandro, Garcia Mario, Pu Min, Gongora Carlos, Neilan Tomas, Makower Della

Cardiac Allograft Vasculopathy Inhibition with AliRocumab:
The CAVIAR Trial

Fearon William, Terada Kossei, Skoda Anette, Luikart Helen, Knowles Josh, Honda Yasuhiro, Woo Christopher, Teuteberg Jeffrey, Khush Kiran

More abstracts from these authors:
Acceptability of Cardiovascular Prevention Strategies Among People With HIV: a Mixed-Methods Study

Durstenfeld Matthew, Levkova Marta, Schaffer Veronica, De Leon Ivan, Dejong Colette, Sauceda John, Gandhi Monica, Hsue Priscilla

PREVENT Heart Failure Equations Underpredict Physician-Adjudicated Heart Failure Events Among People with HIV in the Multi-Center CNICS Cohort

Durstenfeld Matthew, Delaney Joseph, Crane Heidi, Feinstein Matthew, Kyle Ryan, Whitney Bridget, Hoffmann Alexander, Cichowitz Cody, Hunt Peter, Longenecker Chris, Hsue Priscilla, Burkholder Greer

You have to be authorized to contact abstract author. Please, Login
Not Available